{"filings":[{"id":1208837,"accession_number":"0001214659-26-007617","cik":1106861,"company_name":"CS DIAGNOSTICS CORP.","ticker":"CSDX","form_type":"8-K","filed_at":"2026-06-23T14:34:22+00:00","items":["4.02"],"status":"ready","headline":"CS Diagnostics Corp. restates financial statements for 2022-2025 after $499.4M intangible asset error","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board determined financial statements for FY 2022-2025 cannot be relied upon due to improper recognition of $499.4M intangible asset from Sept 4, 2023 transaction.","Company engaged Shah Teelani & Associates as new auditor and KBF Advisory as technical accounting advisor to assist with restatement and re-audit.","Prior audit reports issued by Olayinka Oyebola & Co. also deemed unreliable due to SEC restrictions on that firm.","Restatement expected to materially reduce total assets and stockholders' equity and affect internal control conclusions.","Company plans to convene annual shareholder meeting soon to update shareholders on restatement and remediation progress."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":15574513.306306306,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":"2026-06-23","daily_digest_url":"/daily/2026-06-23","daily_digest_rank":10},{"id":117706,"accession_number":"0001214659-25-015660","cik":1106861,"company_name":"CS DIAGNOSTICS CORP.","ticker":"CSDX","form_type":"8-K","filed_at":"2025-10-31T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CS Diagnostics completes conversion of Preferred B shares to 112.7M common shares; affiliates now hold common stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Conversion of all Series B Preferred Stock held by affiliates CS Interpharm and CS Diagnostics Pharma into 112,652,000 common shares.","Consolidates capital structure for consolidated financial reporting for FY ending Dec 31, 2025.","Affiliates' resales of converted shares remain subject to Rule 144 volume and manner-of-sale restrictions.","Benefits cited: enhanced transparency, improved efficiency, stronger alignment with common shareholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":15574513.306306306,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186887,"accession_number":"0001683168-24-006898","cik":1106861,"company_name":"CS DIAGNOSTICS CORP.","ticker":"CSDX","form_type":"8-K","filed_at":"2024-10-03T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"CS Diagnostics files 8-K describing business and CS Protect Hydrogel product","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filing provides general overview of CS Diagnostics Corp. as a medical distribution company.","Highlights CS Protect Hydrogel spacer gel for prostate cancer radiation therapy.","No specific financial results, contracts, approvals, or material events reported.","Lists company officers but no changes to leadership are disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":15574513.306306306,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}